Cerebrolysin vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
CerebrolysinAnti-Aging & Longevity
Prostamax- Summary
- Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- Variable for the complex; individual peptide fractions: minutes to hours
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- IV, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mL
- 10 mg per day
- Frequency
- Daily for 10–20 days
- Daily for 10–30 days
- Key Benefits
- Promotes neurogenesis and synaptic plasticity
- Approved for stroke rehabilitation (accelerates recovery)
- Alzheimer's disease: slows progression and improves cognition
- Traumatic brain injury recovery
- Enhances memory and executive function
- Neuroprotection against oxidative stress and excitotoxicity
- Anti-amyloid and anti-tau effects
- Mood improvement and reduced anxiety
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Generally well tolerated
- Mild nausea and dizziness (IV infusion)
- Headache at initiation
- Rare: agitation (usually at very high doses)
- +2 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —